Induction therapies in kidney transplantation: the experience of Hospital Pablo Tobon Uribe, Medellín, Colombia 2005-2010 / Catalina Ocampo Kohn ; Arbey Aristizabal Álzate ; John Fredy Nieto Ríos ; Harry Abadía Guzmán ; Walter Mario Ángel Jaramillo ; Carlos Ernesto Guzmán Luna ; Álvaro Mena Hurtado ; Juan José Vanegas Ruiz ; Catalina Vélez Echeverri ; Carlos Enrique Yepes Delgado ; Gustavo Adolfo Zuluaga Valencia  

Público ISBD Título : Induction therapies in kidney transplantation: the experience of Hospital Pablo Tobon Uribe, Medellín, Colombia 2005-2010 Tipo de documento : documento electrónico Autores : Catalina Ocampo Kohn, ; Arbey Aristizabal Álzate, ; John Fredy Nieto Ríos, ; Harry Abadía Guzmán, ; Walter Mario Ángel Jaramillo, ; Carlos Ernesto Guzmán Luna, ; Álvaro Mena Hurtado, ; Juan José Vanegas Ruiz, ; Catalina Vélez Echeverri, ; Carlos Enrique Yepes Delgado, ; Gustavo Adolfo Zuluaga Valencia, Fecha de publicación : 2011 Títulos uniformes : Transplantation Proceedings Idioma : Inglés (eng) Resumen : Background: Induction therapies in kidney transplantation have led to prescriptions of lower doses of maintenance immunosuppression and fewer acute rejection episodes. We sought to assess the use of an affordable monoclonal antibody in terms of the incidences of rejection episodes as well as graft and patient survivals and cytomegalovirus (CMV) and opportunistic infections among our kidney transplant recipients between August 2005 and December 2010. Data were obtained for patients who had more than 20 months’ follow-up. Materials and methods: We retrospectively analyzed data from kidney recipients between August 2005 and December 2010, using descriptive statistics and Kaplan-Meier survival analysis. We performed a multivariate analysis with logistic regression for the dependent variables of rejection episodes and death. Results: Among 425 transplant patients graft survival was 89.2% and patient survival was 94.1% after 76.2% of patients received alemtuzumab, 10.7% daclizumab, 3.6% basilix- imab, 2.4% thymoglobulin, and 7%, no induction therapy. Rejection incidence in general in the first year was 10.8% and CMV incidence 10%. There was an increased risk of rejection among subjects without any us with alemtuzumab induction therapy. Conclusion: Induction therapies show an important reduction in kidney transplant rejection incidence during the first year, allowing low doses of maintenance immunosuppressants, thereby diminishing long-term adverse effects. Alemtuzumab seemed to be a safe alternative with similar results to those obtained with standard immunosuppression. Mención de responsabilidad : C Ocampo, A Aristizabal, J Nieto, H Abadia, W Angel, C Guzman, A Mena, J Vanegas, C Velez, C Aguirre, C Yepes, G Zuluaga Referencia : Transplant Proc. 2011 Nov;43(9):3359-63. DOI (Digital Object Identifier) : 10.1016/j.transproceed.2011.09.006 PMID : 22099796 En línea : https://linkinghub.elsevier.com/retrieve/pii/S0041-1345(11)01181-X Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3585 Induction therapies in kidney transplantation: the experience of Hospital Pablo Tobon Uribe, Medellín, Colombia 2005-2010 [documento electrónico] / Catalina Ocampo Kohn, ; Arbey Aristizabal Álzate, ; John Fredy Nieto Ríos, ; Harry Abadía Guzmán, ; Walter Mario Ángel Jaramillo, ; Carlos Ernesto Guzmán Luna, ; Álvaro Mena Hurtado, ; Juan José Vanegas Ruiz, ; Catalina Vélez Echeverri, ; Carlos Enrique Yepes Delgado, ; Gustavo Adolfo Zuluaga Valencia,  . - 2011. Obra : Transplantation Proceedings Idioma : Inglés (eng) Resumen : Background: Induction therapies in kidney transplantation have led to prescriptions of lower doses of maintenance immunosuppression and fewer acute rejection episodes. We sought to assess the use of an affordable monoclonal antibody in terms of the incidences of rejection episodes as well as graft and patient survivals and cytomegalovirus (CMV) and opportunistic infections among our kidney transplant recipients between August 2005 and December 2010. Data were obtained for patients who had more than 20 months’ follow-up. Materials and methods: We retrospectively analyzed data from kidney recipients between August 2005 and December 2010, using descriptive statistics and Kaplan-Meier survival analysis. We performed a multivariate analysis with logistic regression for the dependent variables of rejection episodes and death. Results: Among 425 transplant patients graft survival was 89.2% and patient survival was 94.1% after 76.2% of patients received alemtuzumab, 10.7% daclizumab, 3.6% basilix- imab, 2.4% thymoglobulin, and 7%, no induction therapy. Rejection incidence in general in the first year was 10.8% and CMV incidence 10%. There was an increased risk of rejection among subjects without any us with alemtuzumab induction therapy. Conclusion: Induction therapies show an important reduction in kidney transplant rejection incidence during the first year, allowing low doses of maintenance immunosuppressants, thereby diminishing long-term adverse effects. Alemtuzumab seemed to be a safe alternative with similar results to those obtained with standard immunosuppression. Mención de responsabilidad : C Ocampo, A Aristizabal, J Nieto, H Abadia, W Angel, C Guzman, A Mena, J Vanegas, C Velez, C Aguirre, C Yepes, G Zuluaga Referencia : Transplant Proc. 2011 Nov;43(9):3359-63. DOI (Digital Object Identifier) : 10.1016/j.transproceed.2011.09.006 PMID : 22099796 En línea : https://linkinghub.elsevier.com/retrieve/pii/S0041-1345(11)01181-X Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3585

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD000155	AC-2011-040	Archivo digital	Producción Científica	Artículos científicos	Disponible

---

1 (1 - 1 / 1) Por página: 25 50 100 200